These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 36585761)

  • 1. Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors.
    Ghaedrahmati F; Esmaeil N; Abbaspour M
    Cancer Commun (Lond); 2023 Feb; 43(2):177-213. PubMed ID: 36585761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Natural Killer Cells for Tumor Immunotherapy.
    Zhang C; Hu Y; Shi C
    Front Immunol; 2020; 11():60. PubMed ID: 32140153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Charting a killer course to the solid tumor: strategies to recruit and activate NK cells in the tumor microenvironment.
    Portillo AL; Monteiro JK; Rojas EA; Ritchie TM; Gillgrass A; Ashkar AA
    Front Immunol; 2023; 14():1286750. PubMed ID: 38022679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment.
    Grote S; Ureña-Bailén G; Chan KC; Baden C; Mezger M; Handgretinger R; Schleicher S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33925968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy?
    Ben-Shmuel A; Biber G; Barda-Saad M
    Front Immunol; 2020; 11():275. PubMed ID: 32153582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy.
    Cao Y; Wang X; Jin T; Tian Y; Dai C; Widarma C; Song R; Xu F
    Signal Transduct Target Ther; 2020 Oct; 5(1):250. PubMed ID: 33122640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Approaches Targeting the Natural Killer-Myeloid Cell Axis in the Tumor Microenvironment.
    Carnevalli LS; Ghadially H; Barry ST
    Front Immunol; 2021; 12():633685. PubMed ID: 33953710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors.
    Jan CI; Huang SW; Canoll P; Bruce JN; Lin YC; Pan CM; Lu HM; Chiu SC; Cho DY
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34663641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
    Zhang C; Liu Y
    Front Immunol; 2020; 11():1295. PubMed ID: 32714324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural Killer T and Natural Killer Cell-Based Immunotherapy Strategies Targeting Cancer.
    Iyoda T; Yamasaki S; Ueda S; Shimizu K; Fujii SI
    Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer cell dysfunction in cancer and new strategies to utilize NK cell potential for cancer immunotherapy.
    Zhang W; Zhao Z; Li F
    Mol Immunol; 2022 Apr; 144():58-70. PubMed ID: 35203022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic treatment strategy: combining CAR-NK cell therapy and radiotherapy to combat solid tumors.
    He J; Yan Y; Zhang J; Wei Z; Li H; Xing L
    Front Immunol; 2023; 14():1298683. PubMed ID: 38162672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
    Parihar R; Rivas C; Huynh M; Omer B; Lapteva N; Metelitsa LS; Gottschalk SM; Rooney CM
    Cancer Immunol Res; 2019 Mar; 7(3):363-375. PubMed ID: 30651290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T.
    Liu Q; Li J; Zheng H; Yang S; Hua Y; Huang N; Kleeff J; Liao Q; Wu W
    Mol Cancer; 2023 Feb; 22(1):28. PubMed ID: 36750830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
    Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
    Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Driving natural killer cell-based cancer immunotherapy for cancer treatment: An arduous journey to promising ground.
    Jiang D; Zhang J; Mao Z; Shi J; Ma P
    Biomed Pharmacother; 2023 Sep; 165():115004. PubMed ID: 37352703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer cell-based strategies for immunotherapy of cancer.
    Vaněk O; Kalousková B; Abreu C; Nejadebrahim S; Skořepa O
    Adv Protein Chem Struct Biol; 2022; 129():91-133. PubMed ID: 35305726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.